Danaher (DHR) Tops Q1 EPS by 6c, Revenues Beat; Lowers FY19 EPS Mid-Point Views Below Consensus, 2Q EPS Guidance Below Consensus,

Danaher (NYSE: DHR) reported Q1 EPS of $1.07, $0.06 better than the analyst estimate of $1.01. Revenue for the quarter came in at $4.9 billion versus the consensus estimate of $4.79 billion.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "During the first quarter, we achieved 5.5% core revenue growth and believe we expanded our market-leading positions across a number of our businesses. Combined with high-single digit adjusted earnings per share growth and good cash flow generation, our performance is a testament to our team\'s focused execution and the power of the Danaher Business System."

Joyce continued, "We are excited about our recently announced agreement to acquire GE Biopharma and continue to expect the deal to close in the fourth quarter of this year. The business will be an excellent complement to our current biologics workflow solutions and will bring a highly innovative, industry-leading product suite to our Life Sciences portfolio. We look forward to welcoming this talented team to Danaher."

GUIDANCE:

Danaher sees Q2 2019 EPS of $1.13-$1.16, versus the consensus of $1.19.

Danaher sees FY2019 EPS of $4.72-$4.80, versus the consensus of $4.79.

For earnings history and earnings-related data on Danaher (DHR) click here.

You May Also Be Interested In

• Keurig Dr Pepper coffee chief to depart ahead of planned split
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Ligand prices $625M convertible notes due 2031 at 0% interest